Thomas, McNerney & Partners
A health care venture firm that invests in life science and medical technology companies at all stages of development. The firm is distinguished from other health care funds by the multi-stage investment expertise of its partners and their long, successful investment track records. The Thomas, McNerney & Partners team has significant experience in helping entrepreneurs start companies, in providing growth capital to emerging companies and in undertaking restructuring transactions such as spin-outs, roll-ups and recapitalizations.
Genomic Health Inc. (GHDX)
A global health company founded in August of 2000 and located in Redwood City, California, is committed to improving the quality of cancer treatment decisions through the research, development and commercialization of genomic-based clinical laboratory services. To that end, the company conducts sophisticated genomic research to develop clinically-validated molecular diagnostics which provide individualized information on response to certain types of therapy, as well as the likelihood of disease recurrence. These diagnostic technologies generate information that healthcare providers and patients can use in making treatment decisions.
Dr. Randy Scott
Considered a pioneer in the field of personalized medicine, Randy Scott is the founder of Genomic Health (GHDX), a molecular diagnostics company, and Incyte Corporation (INCY), a genomic information company. Under Randy’s leadership, Genomic Health developed and launched two revolutionary cancer diagnostics tests. In August, 2012, Randy led a new financing round for Locus Development and took on the role of Chief Executive Officer and InVitae and Locus Development Inc. joined together to advance the collective mission of enabling more personalized, predictive, preventative, and cost-effective healthcare.